| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Indaptus Therapeutics, Inc.
13D/A
INDP · 45339J105
|
27.3% |
10/22/2026
Event 10/16/2026
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.